|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities: | |||||
| Net income (loss) | |||||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||
| Goodwill impairment | |||||
| Indefinite-lived intangible asset impairment | |||||
| Investment impairment | |||||
| Loss on lease terminations | |||||
| Deferred taxes | |||||
| Depreciation of fixed assets and amortization of intangible assets | |||||
| Amortization of debt issuance costs | |||||
| Amortization of debt discount | |||||
| Amortization of debt issuance costs and debt discount | |||||
| Loss (gain) on early extinguishment of debt | |||||
| Stock-based compensation | |||||
| Changes in contingent consideration | |||||
| Net accretion of discount on available-for-sale investments | |||||
| Other net (gains) losses | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable, net | |||||
| Inventories, net | |||||
| Prepaid expenses and other assets | |||||
| Accounts payable | |||||
| Accrued expenses and income taxes payable | |||||
| Other liabilities | |||||
| Payment of contingent consideration | |||||
| Accrued expenses and other liabilities | |||||
| Net cash provided by operating activities | |||||
| Investing activities: | |||||
| Acquisition of GQ Bio Therapeutics GmbH (net of cash acquired) | |||||
| Purchases of fixed assets | |||||
| Purchases of available-for-sale investments | |||||
| Sales of available-for-sale investments | |||||
| Payment of contingent consideration | |||||
| Sale of equity investment | |||||
| Purchases of debt and equity investments | |||||
| Net cash provided by (used in) investing activities | |||||
| Financing activities: | |||||
| Proceeds from exercises of stock options | |||||
| Proceeds from shares issued under employee stock purchase plan | |||||
| Payment of employee withholding taxes on restricted stock unit vests | |||||
| Purchase of treasury stock, inclusive of broker fees | |||||
| Proceeds from Revolving Credit Facility | |||||
| Term loan A facility maturing March 2028 | |||||
| Term Loan B Facility Due December 2026 | |||||
| Total proceeds from Revolving Credit Facility | |||||
| Proceeds from 2029 convertible senior notes | |||||
| Total proceeds from 2029 convertible senior notes | |||||
| Proceeds from Term loan A facility | |||||
| Repayments of convertible senior notes | |||||
| Convertible Senior Notes Due 2022 | |||||
| 2024 Convertible Senior Notes | |||||
| 2025 Convertible Senior Notes | |||||
| Repayment of Term loan facility | |||||
| Term loan A facility maturing March 2028 | |||||
| Term Loan B Facility Due December 2026 | |||||
| Term Loan B Facility | |||||
| Term Loan A Facility | |||||
| Repayment of Revolving Credit Facility | |||||
| Purchase of capped call transactions | |||||
| Debt extinguishment costs | |||||
| Payment of debt issuance and financing costs | |||||
| Payment of contingent consideration | |||||
| Net cash (used in) provided by financing activities | |||||
| Effect of exchange rate changes on cash and cash equivalents | |||||
| Net (decrease) increase in cash and cash equivalents | |||||
| Cash and cash equivalents, beginning of year | |||||
| Cash and cash equivalents, end of year | |||||
| Supplemental cash flow information: | |||||
| Cash paid for interest | |||||
| Cash paid for income taxes, net of refunds | |||||
| Issuance of common stock from conversion of 2022 convertible senior notes | |||||
| Non-cash investing and financing activities: | |||||
| Fixed assets included in accounts payable and accrued liabilities | |||||
| Net additions to contingent consideration liabilities | |||||
| Share repurchases included in accrued liabilities | |||||
| Excise tax on share repurchases included in accrued liabilities | |||||
Loading...
